U.S. task force: End routine prostate cancer screening

NEW YORK (Reuters) - A task force advising the U.S. government on Monday recommended against routine use of the prostate-cancer screening test called PSA, or prostate specific antigen, for lack of a discernible health benefit. Like a draft proposal last October, the U.S. Preventive Services Task Force gave PSA screening a D, for "don't recommend" in healthy men. The reaction was fast and furious ...

Prostate-Cancer Test Not Worth Risk, Advisory Panel Says

The PSA prostate-cancer test used by half of U.S. men older than 40 carries more risks than benefits and shouldn’t be used to diagnose the disease, a U.S. panel said, reaffirming its earlier advice.